TY - JOUR
T1 - Therapeutic Potential of Metabolites from Lactobacillus rhamnosus and Mare's Milk in the Treatment of Dysbiosis
AU - Kozhakhmetov, Samat
AU - Babenko, Dmitriy
AU - Kozhakhmetova, Saniya
AU - Tuyakova, Altynay
AU - Nurgaziyev, Madiyar
AU - Nurgozhina, Ayaulym
AU - Muhanbetganov, Nurislam
AU - Chulenbayeva, Laura
AU - Sergazy, Shynggys
AU - Gulyayev, Alexander
AU - Aljofan, Mohamad
AU - Kushugulova, Almagul
N1 - Funding Information:
Development of technologies using new strains of beneficial microorganisms, enzymes, nutrients, and other kits in the production of special dietary food products (IRN: BR10764998) and the Ministry of Education and Science of the Republic of Kazakhstan (IRN: AP05134659).
Publisher Copyright:
© 2022 Samat Kozhakhmetov et al.
PY - 2022
Y1 - 2022
N2 - Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis. Agents modulating microbial dysbiosis caused by colitis can help in the remission of this disease. The current study describes the potential therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare's milk which have potential therapeutic values on the intestinal microbiota and proinflammatory cytokines. The analysis of the V1-V3 16S rDNA site revealed significant changes in the intestinal microbiome composition before and after treatment in the treated group compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA). So the effect of the study product on dextran sulfate sodium-induced dysbiosis was shown to be more potent than the positive control, 5-ASA. The level of proinflammatory cytokines also decreased under the influence of a biological product.
AB - Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis. Agents modulating microbial dysbiosis caused by colitis can help in the remission of this disease. The current study describes the potential therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare's milk which have potential therapeutic values on the intestinal microbiota and proinflammatory cytokines. The analysis of the V1-V3 16S rDNA site revealed significant changes in the intestinal microbiome composition before and after treatment in the treated group compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA). So the effect of the study product on dextran sulfate sodium-induced dysbiosis was shown to be more potent than the positive control, 5-ASA. The level of proinflammatory cytokines also decreased under the influence of a biological product.
UR - http://www.scopus.com/inward/record.url?scp=85124260525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124260525&partnerID=8YFLogxK
U2 - 10.1155/2022/3851478
DO - 10.1155/2022/3851478
M3 - Article
C2 - 35132375
AN - SCOPUS:85124260525
SN - 2314-6133
VL - 2022
JO - BioMed Research International
JF - BioMed Research International
M1 - 3851478
ER -